8 results about "Morphan" patented technology

Disclosed herein are methods that may be used for the synthesis of benzylisoquinoline alkaloids (“BIAs”) such as alkaloid morphinan. The methods disclosed can be used to produce thebaine, oripavine, codeine, morphine, oxycodone, hydrocodone, oxymorphone, hydromorphone, naltrexone, naloxone, hydroxycodeinone, neopinone, and / or buprenorphine. Compositions and organisms useful for the synthesis of BIAs, including thebaine synthesis polypeptides, purine permeases, and polynucleotides encoding the same, are provided.

This disclosure relates to morphinan compounds and derivatives thereof, pharmaceutically acceptable salts, solvates and hydrates thereof, and compositions comprising the compounds, and use of such compounds and compositions in methods of treating diseases and conditions.

The present invention generally relates to processes for preparing highly pure morphinan-6-one products. The processes involve reducing the concentration of alpha, beta unsaturated ketone compounds present as impurities in morphinan 6 one products or reaction mixtures including morphinan 6 one compounds by treatment with a sulfur-containing compound.

A method of producing promorphinan, morphinan, nal-opioid, and nor-opioid alkaloid products through the increased conversion of a promorphinan alkaloid to a morphinan alkaloid. The method comprises contacting the promorphinan alkaloid with at least one enzyme. Contacting the promorphinan alkaloid with the at least one enzyme converts the promorphinan alkaloid to a morphinan alkaloid.

To provide a spirocyclic morphine derivative having κ-opioid receptor agonist activity. 【Solution means】 A compound represented by the following general formula (I) or a pharmaceutically acceptable salt thereof: TIFF2026086955000362.tif5071 (In the formula, R 1 ~R 5 , R 7 ~R 1 3 represents a hydrogen atom, a C 1-6 alkyl group, etc., R 6 represents a hydrogen atom, a hydroxy group, etc., A represents a heterocycle which may contain at least one heteroatom selected from N, O and S as ring-constituting atoms, etc., W represents a C 1-6 alkylene group, etc., X represents a C 1-6 alkylene group, etc., Y represents a C 1-6 alkylene, etc., Z represents a C 3-7 saturated hydrocarbon ring, etc.).

The presently described technology provides compositions of one or more of oxoacids, polyethylene glycols, and vitamin compounds chemically conjugated to dextrorphan, (+)-17-methylmorphinan-3-ol), to form novel prodrugs and compositions of levorphanol.

To provide a pharmaceutical product useful for the treatment or prevention of opioid δ receptor-related diseases. [Solution] The present invention relates to a pharmaceutical composition comprising a morphinan derivative that exerts opioid δ receptor agonist activity. By administering the pharmaceutical composition provided by the present invention, opioid δ receptor-related diseases (e.g., headaches) may be treated or prevented.

The present invention discloses sinomenine synthase, a preparation method thereof, and its use in directly generating the basic skeleton of morphinan alkaloids from S-reticuline, relating to the fields of gene and enzyme engineering, and solving the problem that the isomerization of existing S-reticuline to R-reticuline is a stumbling block in the synthesis of morphinan alkaloids. The sinomenine synthase is included, and the protease comprises an amino acid sequence selected from SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3 or SEQ ID NO:4. The present invention verifies the biological activity of sinomenine synthase and the uniqueness of the substrate (S-reticuline), laying a solid foundation for the synthetic biology research and industrial application of sinomenine, and then realizing the synthesis of sinomenine in Sinomenium acutum, and at the same time providing a new idea for the synthesis of morphinan alkaloids, establishing an efficient and convenient biosynthetic pathway, and also bringing new challenges to synthetic biology.